Stocks · News reference
Exponent Sees Q3 FY26 Revenue Before Reimbursements Growth Of 8%-10%; Raises FY26 Revenue Before Reimbursements Growth View To 9%-10%
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Neutral on Exponent, Lowers Price Target to $72
UBS analyst Joshua Chan maintains Exponent (NASDAQ:EXPO) with a Neutral and lowers the price target from $75 to $72.
JP Morgan Maintains Overweight on Exponent, Raises Price Target to $90
JP Morgan analyst Tomohiko Sano maintains Exponent (NASDAQ:EXPO) with a Overweight and raises the price target from $80 to $90.